Although rheumatologists consider chimeric antigen receptor T-cell therapy “potentially transformative,” nearly 70% remain ...

UT Southwestern Medical Center researchers have discovered that increasing the levels of a protein called BACH2 makes ...

A first clinical study suggests allogeneic CD19-targeted CAR-T cell therapy can safely induce durable remission in patients ...

Trojan horse” approach may enable ‘antigen-independent’ therapy with potential to treat cancers not traditionally amenable to immunotherapy.

CAR T-cell therapy re-engineers immune cells to target and eradicate high-risk blood cancers, offering potential cures where traditional chemotherapy fails. Initially requiring inpatient care due to ...

Amid growing evidence suggesting circadian rhythms play a critical in the safety and efficacy of CAR T-cell therapy, ...

CAR T-cell therapy shows promise for SCLC, but significant barriers, such as tumor heterogeneity and immunosuppression, must be addressed. Identifying tumor-selective antigens like CDH17, GD2, and ...

CAR T-cell therapy is being adapted for clear cell renal cell carcinoma, targeting CAIX and CD70 to improve efficacy and safety. Early trials like COBALT-RCC and TRAVERSE show promising disease ...

Scientists at the Icahn School of Medicine at Mount Sinai have developed an experimental immunotherapy that takes an ...

A pioneering preclinical study has shown that CAR T cell therapy-a personalized form of immunotherapy used in cancer treatment-could be a highly effective tool against atherosclerosis, the condition ...

Biomarker testing is crucial for personalized oncology care, aiding in risk stratification and treatment decisions, but faces ...

Study suggests CD4+ T cells mediate these immune-related toxicities ...